the lead drug in Elpiscience’s bispecific macrophage engager (BiME) pipeline. Astellas has licensed rights to ES019 and a second unnamed programme and has also taken an option on up to two ...

kuleuven.be Intestinal resident macrophages are at the front line of host defence at the mucosal barrier within the gastrointestinal tract and have long been known to play a crucial role in the ...

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

The scFvs specificity ensures precise targeting of disease markers, while low immunogenicity is reflected in the limited recognition by macrophages, reducing the immune response. Scalability is ...

Plus, news about Foghorn Ther­a­peu­tics, In­cyte, BioN­Tech, Gal­der­ma, Basilea, In­novia, Pharm­ing, bit.bio, Promise Bio, Out­look Ther­a­peu­tics and Tre­vi Ther­a­peu­tics: ...

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

Nature Cancer’s 2024 in Review Focus comprises news, analysis and comment articles on the most exciting advances and biggest challenges of the past year, written by leading researchers ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases.

Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China Ovarian cancer (OC) is the gynecological malignancy with ...

NEW YORK – Immunocore on Tuesday said it began testing its engineered T-cell engager IMC-R117C in patients with PIWIL1-positive colorectal and other cancers in a Phase I/II trial. Immunocore developed ...